NOVOZYMES -B-
NOVOZYMES -B- operates in Diversified Metals & Mining.
NOVOZYMES -B- (NZM2) - Total Liabilities
Latest total liabilities as of December 2023: €14.04 Billion EUR
Based on the latest financial reports, NOVOZYMES -B- (NZM2) has total liabilities worth €14.04 Billion EUR as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NOVOZYMES -B- - Total Liabilities Trend (2016–2023)
This chart illustrates how NOVOZYMES -B-'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NOVOZYMES -B- Competitors by Total Liabilities
The table below lists competitors of NOVOZYMES -B- ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taiwan Taomee Co. Ltd.
TWO:6428
|
Taiwan | NT$54.09 Million |
|
Worlds Inc
OTCQB:WDDD
|
USA | $3.67 Million |
|
AMADEUS IT HOLD -A- - Dusseldorf Stock Exchang
DU:AI3A
|
Germany | €7.01 Billion |
|
PC CONNECTION
MU:PCC
|
Germany | €388.38 Million |
|
Gentor Resources Inc
PINK:GNTOF
|
USA | $1.34 Million |
Liability Composition Analysis (2016–2023)
This chart breaks down NOVOZYMES -B-'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NOVOZYMES -B-'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NOVOZYMES -B- (2016–2023)
The table below shows the annual total liabilities of NOVOZYMES -B- from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €14.04 Billion | +2.07% |
| 2022-12-31 | €13.76 Billion | +9.51% |
| 2021-12-31 | €12.56 Billion | +35.56% |
| 2020-12-31 | €9.27 Billion | +3.45% |
| 2019-12-31 | €8.96 Billion | +8.45% |
| 2018-12-31 | €8.26 Billion | +16.23% |
| 2017-12-31 | €7.11 Billion | +2.78% |
| 2016-12-31 | €6.91 Billion | -- |